Gaush Meditech Ltd. (HK:2407)
:2407
Want to see HK:2407 full AI Analyst Report?
Top Page
Gaush Meditech Ltd.
(2407)
Select Model
Select Model
Rating:64Neutral
Price Target:
HK$5.50
▼(-28.01% Downside)
Action:Downgraded
Date:05/08/26
The score is supported primarily by stabilized financials (moderate leverage, positive earnings, improved 2025 free cash flow) and an attractive valuation (low P/E and high dividend yield). These positives are tempered by weak technicals (price below key moving averages, negative MACD) and recent fundamental softness (revenue decline and margin compression).
Positive Factors
Improved Balance Sheet
Leverage falling to ~0.30 and solid equity (~1.69B vs assets ~2.63B) materially reduces refinancing and liquidity risk versus earlier stressed capital structures. This lasting improvement supports financial flexibility for investment, dividends, or acquisition over the medium term.
Negative Factors
Revenue Decline
A 6.6% revenue decline in 2025 reflects weakening demand or pricing pressure in core markets. Persisting top‑line contraction reduces operating leverage, limits scalability and constrains cash flow and reinvestment capacity, making multi‑quarter recovery necessary to restore growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Balance Sheet
Leverage falling to ~0.30 and solid equity (~1.69B vs assets ~2.63B) materially reduces refinancing and liquidity risk versus earlier stressed capital structures. This lasting improvement supports financial flexibility for investment, dividends, or acquisition over the medium term.
Read all positive factors
Gaush Meditech Ltd. (2407) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$774.93M
Dividend Yield3.48%
Average Volume (3M)147.22K
Price to Earnings (P/E)11.2
Beta (1Y)0.64
Revenue Growth-3.30%
EPS Growth6.27%
CountryHK
Employees884
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.66
Shares Outstanding147,887,860
10 Day Avg. Volume84,250
30 Day Avg. Volume147,220
Financial Highlights & Ratios
PEG Ratio2.34
Price to Book (P/B)0.64
Price to Sales (P/S)0.78
P/FCF Ratio9.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.22
Revenue Forecast (FY)HK$1.72B
Gaush Meditech Ltd. Business Overview & Revenue Model
Company Description
Gaush Meditech Ltd., together with its subsidiaries, researches and develops, produces, and sells ophthalmic medical devices in the People's Republic of China and internationally. The company operates through Proprietary Products, Distribution, Te...
How the Company Makes Money
null...
Gaush Meditech Ltd. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
74
Positive
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.38B | 1.43B | 1.41B | 1.25B | 1.30B |
| Gross Profit | 633.20M | 663.39M | 691.60M | 625.34M | 609.47M |
| EBITDA | 169.71M | 247.31M | 374.31M | 271.91M | 287.20M |
| Net Income | 96.19M | 92.39M | 173.52M | -349.62M | -190.45M |
Balance Sheet | |||||
| Total Assets | 2.63B | 2.57B | 2.84B | 2.72B | 2.43B |
| Cash, Cash Equivalents and Short-Term Investments | 440.94M | 518.99M | 833.04M | 814.16M | 609.00M |
| Total Debt | 507.37M | 552.24M | 664.36M | 756.00M | 2.62B |
| Total Liabilities | 921.65M | 978.12M | 1.15B | 1.23B | 3.06B |
| Stockholders Equity | 1.69B | 1.58B | 1.68B | 1.47B | -656.43M |
Cash Flow | |||||
| Free Cash Flow | 110.47M | 26.57M | 203.44M | 186.41M | 136.44M |
| Operating Cash Flow | 144.23M | 107.78M | 249.04M | 234.42M | 164.49M |
| Investing Cash Flow | 20.82M | 18.55M | -167.65M | -136.04M | 79.83M |
| Financing Cash Flow | -206.60M | -303.09M | -189.94M | 3.08M | 72.84M |
Gaush Meditech Ltd. Technical Analysis
Neutral
7.64
Price Trends
5.28
Negative
6.25
Negative
7.44
Negative
Market Momentum
-0.07
Negative
51.75
Neutral
81.82
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2407, the sentiment is Neutral. The current price of 7.64 is above the 20-day moving average (MA) of 5.10, above the 50-day MA of 5.28, and above the 200-day MA of 7.44, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 51.75 is Neutral, neither overbought nor oversold. The STOCH value of 81.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2407.
Gaush Meditech Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | HK$831.41M | 17.86 | 4.33% | 1.99% | 11.23% | -31.73% | |
64 Neutral | HK$774.93M | 11.17 | 5.68% | 3.48% | -3.30% | 6.27% | |
56 Neutral | HK$5.78B | 9.87 | 6.19% | 2.76% | -4.92% | -19.51% | |
52 Neutral | HK$845.96M | -1.73 | -75.15% | ― | 79.76% | 7.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$1.39B | -4.01 | -12.64% | ― | -53.85% | 12.23% | |
43 Neutral | HK$534.02M | -8.27 | -11.54% | ― | -30.60% | 28.61% |
* Healthcare Sector Average
HK:2407
Gaush Meditech Ltd.
5.24
-0.51
-8.87%
HK:1763
China Isotope & Radiation Corp.
18.07
6.26
53.01%
HK:1846
EuroEyes International Eye Clinic Limited
2.60
-0.31
-10.65%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
2.03
0.36
21.56%
HK:2216
Broncus Holding Corp.
1.01
-1.03
-50.49%
HK:6622
Zhaoke Ophthalmology Ltd.
2.53
0.30
13.45%
Gaush Meditech Ltd. Corporate Events
Gaush Meditech Sets 2026 AGM to Renew Mandates and Expand Share Issuance Flexibility
Apr 29, 2026
Gaush Meditech Ltd has called its annual general meeting for May 28, 2026, in Beijing, where shareholders will vote on routine corporate matters including the adoption of the 2025 audited financial statements and the re-election of three executive...
Gaush Meditech Changes Name of Cayman Share Registrar
Apr 27, 2026
Gaush Meditech Ltd has announced a change in the name of its principal share registrar and transfer office in the Cayman Islands, effective April 17, 2026. The registrar has been renamed from Harneys Fiduciary (Cayman) Limited to Ascentium (Cayman...
Gaush Meditech Wins EU CE Mark for Corneal Confocal Microscope, Bolstering Global Push
Apr 10, 2026
Gaush Meditech’s subsidiary Gaush Neotech has obtained a CE registration certificate for its corneal confocal microscope from DEKRA, confirming compliance with the European Union Medical Device Regulation. This certification validates the pr...
Gaush Meditech Moves to Update Constitution for Virtual Shareholder Meetings
Mar 26, 2026
Gaush Meditech Ltd. plans to amend its existing memorandum and articles of association to align with the Hong Kong Stock Exchange’s Core Shareholder Protection Standards, including provisions to enable shareholders to attend general meetings...
Gaush Meditech Shifts Shareholder Communications to Digital-First Model
Mar 26, 2026
Gaush Meditech Ltd has updated its shareholder communication practices to comply with new Hong Kong listing rules, shifting primarily to electronic dissemination of corporate documents. Future actionable corporate communications will be sent to sh...
Gaush Meditech Lifts Profit and R&D Spending Despite Revenue Dip in 2025
Mar 26, 2026
Gaush Meditech Ltd. reported 2025 revenue of RMB1.38 billion, down 3.4% year on year, while net profit inched up 3.1% to RMB91.2 million and basic earnings per share rose to RMB0.66. Despite softer top-line performance, the company increased resea...
Gaush Meditech Sets March Board Meeting to Approve 2025 Results and Consider Dividend
Mar 16, 2026
Gaush Meditech Ltd. has scheduled a board meeting for March 26, 2026 to review and approve the Group’s annual results for the financial year ended December 31, 2025. The board will also consider the publication of these results and the poten...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.